| Autor: |
Sigal, Eisner, Jacob, Orlin, Eviatar, Nesher, Vadym, Mazhybovsky, Michael, Gurevich, Rachel, Michowiz, Ruth, Rahamimov, Eytan, Mor |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Harefuah. 156(4) |
| ISSN: |
0017-7768 |
| Popis: |
With the introduction of new therapies, the ABO barrier for kidney transplantation has been breached. In the recent decade the reported results with ABO incompatible (ABOi) kidney transplantation are similar to ABO compatible transplantation. We report on our initial experience with ABOi kidney transplantation performed at the Rabin Medical Center.During the period 3/2010 to 4/2015, 22 patients with PRA 0% underwent ABOi living-donor kidney transplantation. This group was compared to 325 non-sensitized live-donor transplant recipients of ABO-match transplants performed at the same period. The desensitization protocol included rituximab (375mg/kg/m2) and three sets of plasmapheresis every other day with IVIG (0.5g/kg) after each plasmapheresis. We compared graft and patient survivals, antibody mediated rejection (AMR) and graft function between the two groups.Graft survival rates at 1, 3 and 5 years in the ABOi group were 95.5% at all intervals and 99.4% for the 1st year and 97.9% at 3 and 5 years after transplant (p=ns). Patient survival rates were 100% at all intervals and 100%, 98.3% and 97.5% at 1,3, and 5 years (p=ns). Two patients (9.1%) in the ABOi group experienced antibody mediated rejection (AMR), one lost his graft. In the ABO-matched group only two patients (0.85%) experienced AMR (p0.05). Creatinine levels at followup were not statistically different between the groups.ABO incompatible kidney transplantation provides an additional option for transplant with excellent results. Strict monitoring of antibody levels should be conducted after ABOi transplantation to timely intervene and prevent AMR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
